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Hemoglobin A1c (HbA1c) is widely used to diagnose diabetes and assess glycemic control in individuals with diabetes. However, non-
glycemic determinants, including genetic variation, may influence how accurately HbA1c reflects underlying glycemia. Analyzing the
NHLBI Trans-Omics for Precision Medicine (TOPMed) sequence data in 10,338 individuals from five studies and four ancestries (6,158
Europeans, 3,123 African-Americans, 650 Hispanics, and 407 East Asians), we confirmed five regions associated with HbA1c (GCK in Eu-
ropeans and African-Americans, HK1 in Europeans and Hispanics, FN3K and/or FN3KRP in Europeans, and G6PD in African-Americans
and Hispanics) and we identified an African-ancestry-specific low-frequency variant (rs1039215 in HBG2 and HBE1, minor allele fre-
quency (MAF) ¼ 0.03). The most associated G6PD variant (rs1050828-T, p.Val98Met, MAF ¼ 12% in African-Americans, MAF ¼ 2%
in Hispanics) lowered HbA1c (0.88% in hemizygous males, 0.34% in heterozygous females) and explained 23% of HbA1c variance
in African-Americans and 4% in Hispanics. Additionally, we identified a rare distinct G6PD coding variant (rs76723693, p.Leu353Pro,
MAF ¼ 0.5%; 0.98% in hemizygous males, 0.46% in heterozygous females) and detected significant association with HbA1c when
aggregating rare missense variants in G6PD. We observed similar magnitude and direction of effects for rs1039215 (HBG2) and
rs76723693 (G6PD) in the two largest TOPMed African American cohorts, and we replicated the rs76723693 association in the UK Bio-
bank African-ancestry participants. These variants inG6PD andHBG2weremonomorphic in the European and Asian samples. African or
Hispanic ancestry individuals carryingG6PD variants may be underdiagnosed for diabetes when screened with HbA1c. Thus, assessment
of these variants should be considered for incorporation into precision medicine approaches for diabetes diagnosis.Introduction
Hemoglobin A1c (HbA1c) is a convenient indirect measure
of long-term exposure to blood glucose concentrations.
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Hematology Working Group, TOPMed Hemostasis Working Group, and National Heart, Lung, and Blood
Institute TOPMed Consortiumto differences in erythrocyte turnover can influence how
accurately HbA1c reflects underlying glycemia.2
We previously conducted a trans-ethnic genome-wide
association study (GWAS) meta-analysis of HbA1c in
159,940 individuals from four ancestries (European, Afri-
can, East Asian, and South Asian). We identified 60 com-
mon (minor allele frequency [MAF] greater than 5%) ge-
netic variants associated with HbA1c, of which 19 were
classified as ‘‘glycemic’’ and 22 as ‘‘erythrocytic’’ based on
the probable biological mechanism through which they
appeared to influence HbA1c levels.3 Genetic variants
affecting HbA1c via erythrocyte biological pathways may
lead to diagnostic misclassification of ambient glycemia
and thus of diabetes status. HbA1c GWAS have so far
focused on genetic variants imputed to HapMap,4 and
therefore genetic discovery efforts have been focused on
common variants. Low-frequency (0.5% < MAF < 5%)
and rare (MAF < 0.5%) genetic variants and their associ-
ated impact on the diagnostic accuracy of HbA1c have
not been systematically examined but are suspected to
occur.5,6 Further, previous GWAS have shown that the
combined effect of HbA1c-related common variants causes
differences in HbA1c that were three times greater in indi-
viduals of African ancestry compared with those of Euro-
pean ancestry (0.8 [%-units] versus 0.25 [%-units]).3 This
relatively large difference in HbA1c was mainly driven
by a single African-ancestry-specific missense variant
(rs1050828-T, p.Val98Met) in the Glucose-6-phosphatase
Dehydrogenase gene (G6PD [MIM: 305900]), which causes
G6PD deficiency (MIM: 300908).7,8 As the genetic
architecture of HbA1c appears to differ by ancestry, as
does type 2 diabetes risk, it is imperative to understand
the genetic basis of HbA1c in different ancestral groups
to ensure that large-effect ancestry-specific variants,
similar to the G6PD variant, are uncovered.9
We sought to identify common, low frequency, and rare
genetic variants (single-nucleotide variants [SNVs] and
structural variations) associated with HbA1c through asso-
ciation analyses in diabetes-free individuals from four an-
cestries by using whole-genome sequencing (WGS) data
from the National Institutes of Health (NIH) National
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The Americafor Precision Medicine (TOPMed) program. We hypothe-
sized that variants that are in the low frequency spectrum
and that have relatively large effects will be detected even
with modest sample sizes. To uncover additional distinct
erythrocytic variants associated with HbA1c, we per-
formed gene-based tests and fine-mapping by using
sequential conditional association analyses of erythro-
cytic loci that reached genome-wide significance in this
study. We then sought replication of genome-wide and
sub-genome-wide TOPMed signals in participants from
the UK Biobank who had European, African, or Asian
ancestry.Material and Methods
Populations and Participants
We included in our analyses 10,338 TOPMed participants without
diabetes from five cohorts: the Old Order Amish study (n ¼ 151),
the Atherosclerosis Risk in Communities Study (ARIC, n ¼ 2,415),
the Framingham Heart Study (FHS, n ¼ 2,236), the Jackson Heart
Study (JHS, n ¼ 2,356), and the Multi-Ethnic Study of Atheroscle-
rosis (MESA, n¼ 3,180). These participants represent four ancestry
groups: Europeans (EA, n ¼ 6,158), African-Americans (AA, n ¼
3,123), Hispanics or Latinos (HA, n ¼ 650), and East Asians (AS,
n ¼ 407) (Table S1). Descriptions of each cohort are available in
the Supplemental Data. Diabetes was defined as fasting glucose
(FG) R 7 mmol/L after R 8 h, HbA1c R 6.5%-units, 2 h glucose
by an oral glucose tolerance test R 11.1 mmol/L, non-fasting
glucose R 11.1 mmol/L, physician-diagnosed diabetes, self-re-
ported diabetes, or use of an antidiabetic medication. Measures
of FG and 2 h glucose made in whole blood were corrected to
plasma levels using the correction factor of 1.13. Individual studies
applied further sample exclusions where applicable, including
pregnancy and type 1 diabetes status.Measurement of HbA1c and Erythrocytic Traits
The National Glycohemoglobin Standardization Program (NGSP)
certified assays10 used to measure HbA1c in each cohort are
indicated in Table S2. HbA1c was expressed in NGSP%-units. Mea-
surements for red blood cell (RBC) count (3 1012/L), hemoglobin
(HB; g/dL), hematocrit (HCT; %), mean corpuscular volume (MCV;
fL), mean corpuscular hemoglobin (MCH; pg), mean corpuscular
hemoglobin concentration (MCHC; g/dL), and red blood cellter, Baltimore,MD 21201, USA; 29Section of PreventiveMedicine and Epide-
e, Boston, MA 02118, USA; 30Whitaker Cardiovascular Institute and Cardi-
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distribution width (RDW; %) were obtained from complete blood
count panels performed using standard assays.Whole-Genome Sequencing
The NHLBI TOPMed program provided WGS, performed at an
average depth of 38 3 by several sequencing centers (New York
Genome Center, Broad Institute of MIT and Harvard, University
of Washington Northwest Genomics Center, Illumina Genomic
Services, Macrogen Corporation, and Baylor Human Genome
Sequencing Center) using DNA from blood. Details regarding
the laboratory methods, data processing, and quality control
are described on the TOPMed website (see URL in the Web Re-
sources section) and in documents included in each TOPMed
accession released on the database of Genotypes and Phenotypes
(dbGaP). Processing of whole genome sequences was harmonized
across genomic centers using a standard pipeline.11
We used TOPMed freeze 5b that comprised 54,508 samples. We
performed variant discovery and genotype calling jointly by using
the GotCloud pipeline across TOPMed parent studies for all sam-
ples. A support vector machine quality filter was trained using
known variants (positive training set) andMendelian-inconsistent
variants (negative training set). The TOPMed data coordinating
center performed additional quality control checks for sample
identity issues including pedigree errors, sex discrepancies, and
genotyping concordance. After site level filtering, TOPMed freeze
5b consisted of 438 million SNVs and 33 million short inser-
tion-deletion variants. Readmappingwas done using the 1000 Ge-
nomes Project reference sequence versions for human genome
build GRCh38.
The study was approved by the appropriate institutional review
boards (IRBs) and informed consent was obtained from all
participants.Statistical Analyses in TOPMed
We first pooled the data across all of the studies, and then we
performed pooled WGS association analysis of HbA1c in each
ancestry separately using GENetic EStimation and Inference in
Structured samples (GENESIS, see URL in the Web Resources sec-
tion)12 on the Analysis Commons.13 We used linear mixed effect
models to test the association of HbA1c with the genetic variants
individually while adjusting for sex and age at HbA1c measure-
ment and study, and allowing for heterogeneous variance across
study groups. We accounted for relatedness within each ancestry
by using an empirical kinship matrix (Genetic Relatedness Ma-
trix [GRM]) calculated globally with Mixed Model Analysis for
Pedigrees and Populations (MMAP, see URL in the Web
Resources section)14,15 and using the pooled sample of all
TOPMed freeze 5b participants (54k participants), and variants
with an MAF R 0.001 (totaling 26.5M variants), without link-
age disequilibrium (LD) pruning. We then meta-analyzed
ancestry-specific results.
We excluded from our single-variant analyses variants with a
minor allele count (MAC) of less than 20 across the combined
samples.We used a significance threshold of p< 23 108 to report
an association as genome-wide significant for common, low-fre-
quency, and rare genetic variants, which was slightly more strin-
gent than the widely adopted p value threshold of 5 3 108 in
GWAS, based on estimations for genome-wide significance for
WGS studies in UK10K.16,17 For the X chromosome, genotypes
were coded as 0 and 2 for males and 0, 1, and 2 for females, and
sex-stratified analyses (analyses conducted separately in males708 The American Journal of Human Genetics 105, 706–718, Octobeand females) were also performed. We performed additional ana-
lyses in AA, adjusted on the sickle cell trait (SCT) variant rs334,
as well as haplotype analyses with this variant, using the R package
haplo.stats.
Because loci that influence HbA1c through erythrocytic mecha-
nisms are expected to cause nonglycemic variation in HbA1c, we
sought to classify HbA1c-associated loci as ‘‘glycemic’’ or ‘‘erythro-
cytic’’ using mediation analyses on FG, HB, MCV, MCH, or MCHC
in TOPMed. If the HbA1c-variant association effect size decreased
bymore than 25%whenwe added FG to the regressionmodel, the
variant was classified as ‘‘glycemic.’’ If a variant was not glycemic,
and if the effect size decreased bymore than 25% upon adding HB,
MCV, MCH, or MCHC to the regression model, the variant was
classified as ‘‘erythrocytic.’’ If association effect sizes were un-
changed by or increased after mediation adjustment, then the
variant was considered ‘‘unclassified.’’
If HbA1c-associated variants remained unclassified by the medi-
ation analyses, we used association analysis results with FG to clas-
sify them as glycemic (p < 0.005), and association analysis results
with erythrocytic traits (HB, MCV, MCH, MCHC, RBC, HCT, or
RDW) to classify them as erythrocytic (p < 0.005). Association re-
sults for FG were obtained from a TOPMed freeze 5b pooled asso-
ciation analysis performed using a linear mixed effect model in
GENESIS, adjusted on age, age squared, sex, body mass index
(BMI), and self-reported ancestry (n ¼ 26,883). Association results
for erythrocytic traits were obtained from several sources. We first
used TOPMed freeze 5b single-variant association analyses per-
formed using a score test in GENESIS and adjusted for age, sex,
and study with a GRM while allowing for heterogeneous variance
across study groups (n ¼ 25,080). The number of individuals
included per study in each analysis is available in Table S3. Ana-
lyses were performed at the University of Washington using the
TOPMed pipeline. We also used association results from published
GWAS in European (UK Biobank and INTERVAL studies; n ¼
173,480),18 Hispanic (Hispanic Community Health Study and
Study of Latinos [HCHS/SOL]; n ¼ 12,502),19 and African Amer-
ican participants (Continental Origins and Genetic Epidemiology
[COGENT] Network [n  16,500]20 and the Candidate gene Asso-
ciation Resource (CARe) Project [n ¼ 7,112]),21 and exome geno-
typing in 130,273 multi-ethnic individuals.22
For loci classified as erythrocytic, we performed sequential con-
ditional analyses to determine the number of distinct signals in
each region. The regions were defined based on LD plots. We
used a Bonferroni correction for the number of genetic variants
in the region with MAC R 20 to define a signal as distinct. We
also performed gene-based and burden tests in GENESIS using a
different selection of rare genetic variants (MAF % 1%) based on
functional annotations (missense, high confidence loss-of-func-
tion, or synonymous variants).
Results from each analysis were combined across ancestries or
between males and females by meta-analysis using METAL.23
The heterogeneity test between males and females was calculated
using the following formula:
ðbmales bfemalesÞ2
SEmales2 þ SEfemales2  23 r3 SEmales3 SEfemales
This assessed the difference in effect sizes between males
(bmales) and females (bfemales) while accounting for correlation
(r) between male and female statistics due to relatedness and was
calculated outside of METAL. LD calculations in the TOPMed
data and regional plots were done, within ancestry group, using
the Omics Analysis, Search and Information System (OASIS, seer 3, 2019
Figure 1. Manhattan Plot of the Meta-
Analysis of HbA1c in Non-Diabetic Indi-
viduals in TOPMed Cohorts
The –log10 (p value) for each single-nucle-
otide variant on the y axis is plotted
against the build 38 genomic position
on the x axis (chromosomal coordinate).
The dashed horizontal line indicates the
genome-wide significance threshold of
p ¼ 2 3 108. The y axis was truncated
for ease of interpretation.URL in the Web Resources section). Functional annotations were
performed using the WGS Annotator (WGSA).24
Statistical Analyses in the UK Biobank
We used the UK Biobank (UKBB, see URL in theWeb Resources sec-
tion), a prospective cohort studywith deep genetic andphenotypic
data collected on approximately 500,000 individuals aged between
40 and 69 at recruitment fromacross theUnitedKingdom, as an in-
dependent sample for external replication of our findings. The
centralized analysis of the genetic data, includinggenotypequality,
population structure and relatedness of the genetic data, and effi-
cient phasing and genotype imputation, has been described exten-
sively elsewhere.25 Two similar arrays were used for genotyping
(Applied Biosystems UK Biobank Lung Exome Variant Evaluation
andUK Biobank AxiomArrays) and pre-phasingwas performed us-
ingmarkers present on both arrays. Phasing on the autosomes was
carried out using SHAPEIT3 and 1000 Genomes phase 3 panel to
help with the phasing of non-European ancestry samples. Imputa-
tionswere carried out using the IMPUTE4 programwith theHaplo-
typeReferenceConsortium(HRC) referencepanel orwith amerged
UK10K and 1000 Genomes phase 3 reference panel. For chromo-
some X, haplotype estimation and genotype imputation were
carried out separately on the pseudo-autosomal and non-pseudo
autosomal regions.
We identified UKBB African-ancestry participants using the
following three self-reported ethnicities: ‘‘Caribbean,’’ ‘‘African,’’
and ‘‘Any other Black background.’’ We identified UKBB Euro-
pean-ancestry participants using the following three self-reported
ethnicities: ‘‘White,’’ ‘‘British,’’ and ‘‘Irish.’’ We identified UKBB
Asian-ancestry participants using the ‘‘Chinese’’ self-reported
ancestry. We excluded participants with diabetes defined by the
use of antidiabetic medication, self-reported physician diagnosis,
FG R 7 mmol/L, or non-fasting glucose R 11.1 mmol/L or
HbA1cR 6.5%-units. Because African-ancestry UKBB participants
were admixed, we generated principal components (PCs) using
smartPCA23,24 (see URL in the Web Resources section) based on
72,300 common genetic variants in low LD selected with PLINK
(see URL in theWeb Resources section).25 For each PC, ethnic out-
liers lying more than 6 SD away from the mean were excluded.
Additionally, we excluded samples with high heterozygosity andThe American Journal of Human Genhigh missing rate, sex aneuploidy, or
different genomic and stated sex. We
used the R package Scalable and Accurate
Implementation of Generalized mixed
model (SAIGE, see URL in the Web Re-
sources section)26 and linear mixed effect
models to evaluate the association of
TOPMed genome-wide and sub-genome-
wide signals with HbA1c, adjusting forage and sex, and using a GRM. We also used UKBB exome
sequence data available in 50K participants to check the concor-
dance of genotypes with imputed data for rare variants.Results
HbA1c-Associated Regions Using WGS
We included in our analyses 10,338 TOPMed participants
representing four ancestry groups: EA (n ¼ 6,158), AA
(n ¼ 3,123), HA (n ¼ 650), and AS (n ¼ 407; Table S1).
TOPMed studies were composed of middle- to older-aged
participants of EA, AA, HA, or AS ancestry with comparable
mean HbA1c, mean fasting glucose (FG), and mean hemo-
globin (HB, Table S4). A total of 13,079,661 variants (EA),
21,443,543 variants (AA), 9,567,498 variants (HA), and
6,567,324 variants (AS) passed filters and were included
in the analyses. QQ-plots and Manhattan plots of WGS as-
sociations with HbA1c from ancestry-specific analyses and
the meta-analysis are provided in Figure 1 and Figures S1
and S2. Using a significance threshold of p < 2 3 108 to
report an association as genome-wide significant, we de-
tected five regions associated with HbA1c, including one
locus that had not been identified in the trans-ethnic
GWAS meta-analysis of HbA1c3 (a low-frequency AA-spe-
cific variant, rs1039215 in HBG2 [MIM: 142250] and
HBE1 [MIM: 142100], MAF ¼ 0.03). Regional plot for the
HBG2 and HBE1 locus is provided in Figure S3. The
four other SNVs were located in regions previously identi-
fied as associated with HbA1c in trans-ethnic meta-
analyses3: rs2971670 in GCK (MIM: 138079) on chromo-
some 7 (Pmeta ¼ 1.7 3 109, mainly associated in EA and
AA, r2 ¼ 0.59, D0 ¼ 1 with rs4607517, the index SNV in
published GWAS), rs17476364 in HK1 (MIM: 142600) on
chromosome 10 (Pmeta ¼ 3.1 3 1021, mainly associated
in EA and HA, r2 ¼ 0.10, D0 ¼ 1 with rs10823343, r2 ¼
0.18, D0 ¼ 0.50 with rs4745982, index SNVs in publishedetics 105, 706–718, October 3, 2019 709
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710 The American Journal of Human Genetics 105, 706–718, OctobeGWAS), rs113373052 in FN3K (MIM: 608425) on chromo-
some 17 (Pmeta ¼ 4.5 3 1010, associated in EA, r2 ¼ 0.92,
D0 ¼ 0.99, with rs1046896, index SNV in published
GWAS), and rs1050828 in G6PD on chromosome X
(Pmeta ¼ 5.13 10210, associated in AA and HA, monomor-
phic in the other ancestries).3 The top SNV or structural
variant in each region detected at the genome-wide
threshold (p < 2 3 108) is indicated in Table 1, and
the top one detected at the sub-genome-wide threshold
(p < 5 3 107) is indicated in Table S5. Genetic association
results (summary statistics) are available in the Type 2 Dia-
betes Knowledge Portal (see URL in the Web Resources
section).
Classification of HbA1c-Associated Loci Based on Their
Biological Pathways
Because loci that influence HbA1c through erythrocytic
pathways are expected to cause nonglycemic variation
in HbA1c, we sought to classify HbA1c-associated loci as
glycemic or erythrocytic through the use of mediation an-
alyses in TOPMed and association analyses with glycemic
and erythrocytic traits in TOPMed or using results from
the literature. Mediation analyses and look-up in WGS
analysis of FG in TOPMed classified the GCK variants as
glycemic (Tables S6–S8). Association analyses with eryth-
rocytic traits in published GWAS and in TOPMed showed
that the rs17476364-C allele, in the HK1 gene, was posi-
tively associated with HB, MCV, MCH, MCHC, red blood
cell count (RBC), HCT, and RDW in Europeans18 and
that the rs1050828-T allele, in the G6PD gene, was posi-
tively associated with MCH in African-Americans and
MCV in African-Americans and Hispanics or Latinos and
negatively associated with HCT and HB in African-Ameri-
cans and RBC and RDW in African-Americans and His-
panics or Latinos19–21 (Tables S6, S8, and S9). Results of
the mediation and association analyses in TOPMed are
available in Tables S6 and S8 for the genome-wide variants
and in Tables S7 and S10 for the sub-genome variants. As-
sociation results with erythrocytic traits from published
GWAS are available in Table S9. Among the 26 variants
meeting the sub-genome-wide threshold, four were
common and 22 were low frequency or rare. Two of the
common HbA1c-associated variants were reported previ-
ously:3 the glycemic variant at G6PC2 (MIM: 608058)
and the erythrocytic variant at TMPRSS6 (MIM: 609862).
Among the genome-wide significant loci, HK1 (EA) and
G6PD (AA and HA) were classified as erythrocytic, as was
the low-frequency variant rs1039215 in HGB2 and
HBE1, which was negatively associated with HB, HCT,
MCV, and MCH. The significant FN3K variant was
unclassified.
Characterization of Distinct Signals at Erythrocytic
HbA1c-Associated Loci
For loci classified as erythrocytic (HK1, HBG2 and HBE1
and G6PD), we performed sequential conditional analyses
to detect distinct signals in addition to the top SNV. Ther 3, 2019
Figure 2. Regional HbA1c Association
Plots in the G6PD Region in Non-Dia-
betic African-Americans and Hispanics in
TOPMed Cohorts
Association plots are displayed separately
in African-Americans (left side) and in His-
panics (right side). Single-nucleotide vari-
ants are plotted with their p values
(-log10 values, y axis) as a function of build
38 genomic position on chromosome X
(x axis). The local linkage disequilibrium
(LD) structure (r2—top or D0—bottom)
between the top associated single-nucleo-
tide variant, rs1050828 (red triangle), and
correlated proxies is indicated in color
according to a blue-to-red scale from
r2/D0 ¼ 0 to 1, and this local LD structure
was calculated separately in non-diabetic
African-American and Hispanic TOPMed
cohorts.regions were defined, based on LD plots, as5 60kb region
around HK1, þ/ 250kb region around HBG2 and HBE1,
and 5 500kb region around G6PD (Figures S3–S5). We
did not detect secondary associations in the HK1 and
HBG2 and HBE1 regions at a threshold of 4.3 3 105 and
8.5 3 106 respectively. In the G6PD region, the top SNV
(rs1050828, p.Val98Met, T-allele frequency 12% in AA,
2% in HA, and 0% in EA and AS) was associated with lower
HbA1c in both AA and HA. This SNV accounted for 23% of
HbA1c variance in AA and 4% in HA. The LD in the G6PD
region is complex, with a strong haplotype effect in AA
and HA (Figure 2). By performing conditional analyses on
the top SNV (rs1050828), we were able to detect an addi-
tional rare signal (G-allele frequency 0.5%) in AA
(rs76723693, p.Leu353Pro, Bcond ¼ 0.50, Pcond ¼ 2.8 3
1015) that was distinct from rs1050828 (r2 ¼ 0.0006,
D0 ¼ 1, Figure 3). The threshold to detect an additional
signal was fixed to 1.7 3 105 in AA and 4.5 3 105 in
HA. The three other SNVs located in the same region that
were sub-genome-wide significant in the main analysis
(rs143745197, rs184539426, and rs189305788) were
not significant after adjusting for both rs1050828 and
rs76723693. We detected significant or suggestive associa-
tions by using gene-based (p ¼ 9.7 3 1011) and burden
tests (p ¼ 4.7 3 105) when aggregating 15 missense rare
variantswithMAF% 1% inG6PD (Table S11). Because asso-
ciation from SKAT was more significant than the associa-
tion of rs76723693 from single-SNV association analysis,
it suggested that several rare missense variants in G6PD
were associatedwithHbA1c.Weperformed additional asso-
ciation and conditional analyses in G6PD for missense var-
iants with 10 <MAC < 20. In addition to rs76723693, one
raremissense variant (rs5030872,MAF¼0.002)was sugges-
tively associated with HbA1c (B ¼ 0.64, p ¼ 3.4 3 106)The American Journal of Human Geand became significantly associated
with HbA1c when we adjusted for
both rs1050828 and rs76723693
(Bcond ¼ 0.71, Pcond ¼ 1.3 3 109).
The HBG2 and HBE1 variant rs1039215 (p ¼ 2.0 3 109)
is located at 327 kb from the SCT variant rs334 (p ¼ 2.9 3
108). A recent paper reported rs1039215 to be in LD (r2 >
0.2) with the SCT variant (rs334, r2¼ 0.24, D0 ¼ 0.83) and
correlated with HBG2 gene expression in whole blood.27
To determine whether rs1039215 was distinct from
rs334, we calculated LD and performed conditional ana-
lyses. In TOPMed, rs1039215 was in modest LD with
rs334 (r2 ¼ 0.30, D0 ¼ 0.88, Figure S3), and conditioning
on rs334 attenuated its association (decrease in p value
from 2.0 3 109 to 2.0 3 103, Table S12). These results
suggest that the association of rs1039215 with HbA1c
may be explained by the SCT rs334 variant. Nevertheless,
the haplotype rs334-A and rs1039215-G was more signifi-
cantly associated with HbA1c than were the haplotypes
rs334-A and rs1039215-A and rs334-T and rs1039215-G
(Table S13). Thus, the association of the variant
rs1039215 in HBG2 and HBE1 could be partially distinct
from the known association at the SCT variant. In our
AA sample, 12 individuals each carried two copies of the
rs1050828-T allele and at least one copy of the
rs1039215-G allele and had a mean HbA1c of 4.60 (0.41)
versus 5.65 (0.39) for the 2,372 individuals who carried
no risk allele at the two variants (Table S14).
HbA1c-Lowering Effects of G6PD Variants in AA and HA
In sex-stratified analyses in AA, the G6PD rs76723693
variant was associated with a decrease in HbA1c of
0.98%-units (95% CI 0.51–1.44) per allele in hemizygous
men and 0.46%-units (95% CI 0.26–0.66) in heterozygous
women, whereas the G6PD rs1050828 variant was associ-
ated with a decrease in HbA1c of 0.88%-units (95% CI
0.81–0.95) per allele in hemizygous men and 0.34%-units
(95% CI 0.30–0.39) in heterozygous women (Table 2 andnetics 105, 706–718, October 3, 2019 711
Figure 3. Sequential Conditional Ana-
lyses in the G6PD Region in Non-Dia-
betic African-Americans and Hispanics in
TOPMed Cohorts
Association plots are displayed separately
in African-Americans (left side) and in
Hispanics (right side). Single-nucleotide
variants are plotted with their p values
(-log10 values, y axis) as a function of build
38 genomic position on chromosome X
(x axis). The local linkage disequilibrium
(LD) structure (r2) between the top associ-
ated single-nucleotide variant (red triangle)
and correlated proxies is indicated in
color according to a blue to red scale from
r2 ¼ 0 to 1 and was calculated separately
in non-diabetic African-American and in
Hispanic TOPMed cohorts. Significance
thresholds to declare an association signal
as distinct are indicated by a dashed grey
line (p ¼ 1.7 3 105 in African-Americans
and p ¼ 4.5 3 105 in Hispanics, based
on the number of single-nucleotide vari-
ants in the regionwith aminor allele count
greater than 20).Figure 4). We detected heterogeneity in effect sizes be-
tween males and females for rs1050828 (Phet ¼ 0.008)
but not for rs76723693 (Phet ¼ 0.19). In HA, the G6PD
rs1050828 variant was associated with a decrease in
HbA1c of 0.84%-units (95% CI 0.47–1.22) per allele in
hemizygous men and 0.25%-units (95% CI 0.06–0.45)
in heterozygous women (Table 3 and Figure 4). Upon ad-
justing on the SCT variant, rs334, we found that the asso-
ciation of these two SNVs did not attenuate (Table S12).
Population Reclassification of Diabetes Diagnosis Based
on G6PD Variants
Despite the lower diagnostic sensitivity of HbA1c28,29
compared to FG or 2 h glucose in an oral glucose tolerance
test, diabetes screening using only HbA1c is not uncom-
mon in clinical practice due to its lower intra-individual
variability and the convenience of performing the test in
the non-fasting state. To assess the potential public health
impact ofG6PD variants in AA, we designed a hypothetical712 The American Journal of Human Genetics 105, 706–718, October 3, 2019scenario, using National Health
and Nutrition Examination Survey
(NHANES, see URL in the Web Re-
sources section) 2015–2016, and esti-
mated the number of African Ameri-
cans and Hispanics whose diagnosis
of diabetes would have been missed
if they had been screened by a single
HbA1c measurement without confir-
matory testing by direct glucose mea-
surements. We assumed that the ef-
fects of the two G6PD variants
rs1050828 and rs76723693 were not
accounted for, and the standard diag-
nostic threshold of R6.5% was uni-formly applied to the entire population. We restricted the
NHANES analytic sample to adults aged R18 years and
who self-identified as ‘‘Non-Hispanic Black’’ or ‘‘Mexican
American/Other Hispanic’’ respectively. We defined the
proportions of individuals carrying the G6PD variants by
their allele frequencies and assumed that the ‘‘true’’
HbA1c values of these individuals were higher by their ge-
netic effect sizes from the association analyses.
In non-Hispanic Black individuals (n ¼ 1,227), an esti-
mated 2.32% with HbA1c< 6.5%-units may be considered
to have diabetes upon accounting for the effect size and
observed allele frequency of the common G6PD variant,
rs1050828. An additional 0.13% with HbA1c < 6.5%-units
may be considered to have diabetes upon accounting for
the effect of the rare G6PD variant, rs76723693. In
Mexican American/Other Hispanic individuals (n ¼
1,768), an additional 0.26% with HbA1c < 6.5%-units
may be considered to have diabetes due to the effect of
rs1050828. According to the 2016 United States Census
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The AmericaBureau, approximately 30.14 and 39.33 million adults
identified themselves as African American and Hispanic
adults, respectively; this suggests that 740,000 African
American adults, of whom 40,000 would have diabetes
attributed to the rare variant, rs76723693, and 100,000
Hispanic adults with diabetes would remain undiagnosed
when screened by a single HbA1c measurement if this ge-
netic information was not taken into account (Tables S15
and S16).
Replication of Results in the UKBB
We selected a total of 5,311 African-ancestry, 398,122 Euro-
pean-ancestry, and 1,331 Asian-ancestry non-diabetic
UKBB participants for replication. In the African-ancestry
sample, 2,247 participants were males, mean age (SD) was
51.2 (7.8), andmean HbA1c (SD) was 5.5 (0.5). In the Euro-
pean-ancestry sample, 179,055 participants were males,
mean age (SD) was 56.6 (8.0), and mean HbA1c (SD) was
5.3 (0.3). In the Asian-ancestry sample, 490 participants
were males, mean age (SD) was 52.1 (7.6), and the mean
HbA1c (SD) was 5.5 (0.4) (see Supplemental Data).
The four variants of interest (rs334 [SCT], rs1039215
[HBG2], rs76723693, and rs1050828 [G6PD]) had a good
quality of imputation (info score > 0.50, Table 4). We
observed significant and consistent associations of the
two G6PD variants with HbA1c (rs1050828-T, B ¼ 0.38,
p < 2.2 3 1016 and rs76723693-G, B ¼ 0.20, p ¼
0.008, Table 4). The association of the rare G6PD
rs76723693-G variant was even more significant when
both G6PD variants were in the model (B ¼ 0.25, p ¼
5.1 3 105). We observed a high concordance between
exome sequence data and imputed genotypes for the rare
G6PD rs76723693 SNV. Only seven individuals among
49,741 had a discordance of genotypes between imputed
and exome sequence data, using dosage ranges of [0–0.2],
[0.9–1.1], and [1.8–2.0] to classify AA, GA, and GG
genotypes respectively. The additional G6PD variant with
10 < MAC < 20 in TOPMed, rs5030872, was not present
in the UKBB. Thus, GWAS, even with large sample sizes,
are limited to genetic variants present in imputation refer-
ence panels. We did not detect significant associations of
HBG2 and SCT variants with HbA1c in the UKBB. Associa-
tion results for the TOPMed genome-wide and sub-
genome-wide associations inUKBB are provided in Tables 4
and S17. In UKBB African-ancestry participants, in
addition to G6PD, we replicated the known HbA1c
loci GCK and FN3K. We also found nominal asso-
ciations with HbA1c (p < 0.05) for rs77974976 in
CTTNBP21 (B ¼ 0.12, p ¼ 0.02), rs143745197 in
ATP2B3 (B ¼ 0.21, p ¼ 2.4 3 106), and rs189305788
in F8 (B ¼ 0.18 p ¼ 0.01). The SNV rs143745197 was in
LD with our main G6PD signal (B ¼ 0.02, p ¼ 0.64 after
conditioning on rs1050828) and the SNV rs189305788
was in LD with our additional distinct G6PD signal
(B ¼ 0.03, p ¼ 0.83 after conditioning on rs76723693).
We did not replicate the sub-genome-wide signal in
XPNPEP1 (B ¼ 0.01, p ¼ 0.95). However, the geneticn Journal of Human Genetics 105, 706–718, October 3, 2019 713
Figure 4. Mean HbA1c Levels According
to Genotypes at Both G6PD Variants
(rs76723693 and rs1050828) and Strati-
fied by Sex
Plots are displayed separately in African-
Americans (AA, left and center) and in
Hispanics (HA, right). Due to the limited
sample size of African-American women
carrying two copies of the rare G allele at
rs76723693, they are not represented on
this plot. In AA, the G6PD rs76723693
variant was associated with a decrease in
HbA1c of 0.98%-units (95% confidence in-
terval [CI] 0.51–1.44) per allele in hemizy-
gous men and 0.46%-units (95% CI 0.26–
0.66) in heterozygous women; whereas
theG6PD rs1050828 variant was associated
with a decrease in HbA1c of 0.88%-units
(95% CI 0.81–0.95) per allele in hemizygous men and 0.34%-units (95% CI 0.30–0.39) in heterozygous women In HA, the G6PD
rs1050828 variant was associated with a decrease in HbA1c of 0.84%-units (95% CI 0.47–1.22) per allele in hemizygous men and
0.25%-units (95% CI 0.06–0.45) in heterozygous women.variant rs551601853 was rarer in the UKBB compared to
TOPMed (MAC¼ 6 in UKBB versusMAC¼ 20 in TOPMed).
In UKBB European-ancestry participants, we replicated the
known HbA1c loci: GCK, HK1, FN3K, G6PC2, TMC8, and
TMPRSS6. We did not replicate the Asian-specific signal
in EMCN.Discussion
Through association analysis and fine-mapping of HbA1c-
associated loci in 10,338 individuals from four different
ancestries, we demonstrated how deep large-scale WGS
can be used to identify common, low frequency, and rare
genetic variants that influence nonglycemic variation in
HbA1c in multi-ethnic populations. While fewer loci
were uncovered in this WGS study compared to array gen-
otyping in larger studies, WGS did enhance our under-
standing of the allelic heterogeneity at knownHbA1c-asso-
ciated loci. Moreover, the multi-ethnic panel provided
more resolution on the range of alleles and haplotype ef-
fects within these loci. We confirmed four known regions
associated with HbA1c (the glycemic GCK, erythrocytic
HK1 and G6PD, and unclassified FN3K and/or FN3KRP re-
gions) and identified two AA-specific low frequency or
rare erythrocytic variants in G6PD (rs76723693) and
HBG2 and HBE1 (rs1039215); these variants, to our knowl-
edge, have not been reported in previous trans-ethnic
GWAS meta-analyses of HbA1c. The magnitude and direc-
tion of effect of the association of rs76723693 and
rs1039215 with HbA1c was similar in the two largest
TOPMed AA cohorts (JHS and MESA, Table S18). The asso-
ciation of rs76723693 with HbA1c was replicated in UKBB
African-ancestry participants. We detected significant asso-
ciation through the use of a gene-based test when aggre-
gating rare missense variants in G6PD; this result indicates
that other rare missense variants in G6PD, in addition to
rs76723693, are associated with HbA1c. We showed that
the association of the HBG2 and HBE1 variant,714 The American Journal of Human Genetics 105, 706–718, Octobers1039215, with HbA1c was partially distinct from the
known SCT rs334 variant in HBB (MIM: 141900), and
this suggests that genetic variation at hemoglobin genes
other thanHBBmay also influence HbA1c. Individuals car-
rying both the G6PD variant (rs1050828) and the HBG2
and HBE1 variant (rs1039215) had even lower HbA1c
than did those carrying only one of the two variants.
Hemizygous males and homozygous females for the
G6PD rs1050828-T allele who carried one or more copies
of the HBG2 rs1039215-G allele had a mean HbA1c that
was 1.05%-unit lower than the mean HbA1c of individuals
who carried none of these alleles.
The HbA1c variant in AA, rs1039215 on chromosome
11, lies in an intron of the hemoglobin subunit gamma 2
gene HBG2 and the hemoglobin subunit epsilon 1 gene
HBE1. HBG2, in addition to HBG1, encodes the gamma
chain of hemoglobin, which combines with two alpha
chains to form fetal hemoglobin. Fetal hemoglobin is
known to interfere with the measurement of HbA1c by
some laboratory assays,30–32 and so persistence of fetal he-
moglobin may be a mechanism through which rs1039215
influences HbA1c measurements. While a small degree of
analytic interference with SCT has been reported for the
Tosoh 2.2 and G7 assays used by JHS, MESA, and ARIC to
measure HbA1c (see NGSP website URL in the Web Re-
sources section),33,34 no interference has been reported
for the Bio-Rad Variant II Turbo assay used by UKB35 (Table
S2). Thus, assay interference may explain the lack of asso-
ciation of rs334 with HbA1c in UKBB. Alternatively, as our
haplotype analysis indicated that the haplotype contain-
ing both rs334-A in HBB and rs1039215-G in HBG2 was
likely the main driver of this signal in the region, the
true causal variant could be another variant within this
haplotype that partially explains the reported association
of rs334 with HbA1c.
Both variants identified in G6PD in AA are missense
and pathogenic variants for G6PD deficiency (as reported
in ClinVar [VCV000037123 and VCV000010388]), an
X-linked genetic disorder characterized by a defect inr 3, 2019
Table 3. Analysis of HbA1c Associations with rs1050828, X:154536002, Alternate Allele T, in Non-Diabetic African-Americans and
Hispanics in TOPMed Cohorts
- African-Americans Hispanics
- N AAFa Beta SE p Value
% Of Variance
Explained n AAFa Beta SE p Value
% of Variance
Explained
All 3,123 0.12 0.41 0.01 8.4E-205 0.23 650 0.02 0.37 0.07 8.3E-07 0.04
Males 1,269 0.12 0.44 0.02 2.3E-148 0.35 323 0.01 0.45 0.11 3.5E-05 0.05
Females 1,854 0.12 0.37 0.02 2.7E-69 0.14 327 0.02 0.28 0.10 4.5E-03 0.02
aAAF: alternate allele frequencyglucose-6-phosphate dehydrogenase enzymatic action;
this defect causes erythrocytes to break down prematurely.
Thus, the mechanism through which these G6PD variants
lower HbA1c is most likely shortening of the erythrocytic
lifespan (Table S19). Assuming random X inactivation,
we would expect the difference between hemizygousmales
and males who do not carry the rs1050828-T variant to be
two times larger than the difference between heterozygous
females and females who do not carry the rs1050828-T
variant; however, in this study, we observed a slightly
lower than expected effect in females. We posit that this
heterogeneity of genetic effects based on sex may be due
to X-linked dosage compensation and not actual sex differ-
ences.36 While these G6PD variants lower HbA1c in AA,
with the same direction of effect as the sickle cell trait
variant,5 we note that the lowering effect of these genetic
variants on HbA1c does not explain the higher mean
HbA1c in AA individuals compared to EA individuals
with similar glycemia that has been reported in observa-
tional studies.37,38
We found that rs1050828, the common G6PD variant
in AA, was also associated with HbA1c in HA (sample
composed of 51% Mexican, 14% Dominican, 14% Puerto
Rican, 11% South American, and 10% others) suggestingTable 4. Association Results of the Main TOPMed Signals in the UK Bi
- - - - - Africa
MarkerIDa rsID
Closest
Gene
Alternate
Allele
Imputation
Info Score
Alter
Allel
Freq
7:44186502 rs2971670 GCK T 0.999 0.18
10:69334748 rs17476364 HK1 C 0.997 0.01
11:5464062 rs1039215 HBG2 and
HBE1
G 0.939 0.99
11:5227002 rs334 SCT A 0.892 0.02
17:82739582 rs113373052 FN3K T 0.998 0.27
X:154533025 rs76723693 G6PD G 0.638 0.004
X:154536002 rs1050828 G6PD T 0.920 0.16
aMarkerID is defined as Chromosome:Position. Positions are indicated on Build 3
The Americathat carriers of this variant are likely to be underdiagnosed
if a single HbA1c measurement is used to screen two of the
largest racial and ethnic minorities in the United States for
diabetes. If G6PD variants were ignored, we estimate that
approximately 840,000 African American and Hispanic
adults with diabetes would remain undiagnosed. Because
Hispanic populations are ancestrally diverse, and that
diversity includes a range of African ancestry (7% of
HA in our study have > 50% AA ancestry and 25%
have > 15% AA ancestry), G6PD variants were expected
to occur at some lower frequency in HA compared to AA.
Given that there is no universal screening for G6PD defi-
ciency in North America, asymptomatic carriers are un-
likely to know their G6PD status.7 While misclassification
of diabetes status at the population level was largely driven
by the common G6PD variant rs1050828 and not the rare
rs76723693 variant (found in 0.5% of the AA population),
in this era of precision medicine, there is a growing need
for clinical practice to account for the impact of rare ge-
netic variants with clinically meaningful effects on
routinely performed diagnostic tests even if the proportion
of carriers in the population is small. We also predict that
other G6PD deficiency variants, particularly common in
African, Mediterranean, and Asian populations,39 willobank
n Ancestry European Ancestry
nate
e
uency Beta SE p Value
Alternate
Allele
Frequency Beta SE p Value
0.06 0.01 2.2E-07 0.18 0.04 0.001 7.8E-
233
0.08 0.04 5.7E-02 0.11 0.12 <1E-
04
<1E-
250
0.02 0.05 6.0E-01 – – – –
0.002 0.04 9.6E-01 – – – –
0.03 0.01 8.7E-03 0.31 0.03 0.001 2.2E-
214
0.20 0.08 7.6E-03 – – – –
0.38 0.01 7.3E-
310
– – – –
8.
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impact HbA1c’s utility as a diagnostic measure. Until ge-
netic information is universally accessible to adjust diag-
nostic thresholds of imperfect biomarkers, our findings
support current clinical practice guidelines from the Amer-
ican Diabetes Association which recommends the use of
both FG and HbA1c in combination for diabetes diagnosis,
especially given that the diagnostic level of HbA1c is con-
servative relative to FG.40
Strengths of this investigation include the analysis of
extremely high-quality deep sequence data from a large,
multi-ancestry sample including five studies and four an-
cestries to investigate the association of genetic variation
across the full allelic spectrum with HbA1c, a diagnostic
test that is central to the care of individuals with diabetes.
As previous GWAS on HbA1c have included a smaller sam-
ple of Hispanic ancestry, this study represents a larger ge-
netic discovery effort for ethnic minorities in the United
States. Our study demonstrates that both common and
rare genetic variation differ across ancestries and inform
the unique genetic architecture of HbA1c. We recognize
limitations. We acknowledge that even with a high impu-
tation score, the imputation accuracy of rare variants in
the UKBB may not be as optimal as that of common vari-
ants. Our hypothetical scenario using NHANES data to
assess the population impact of G6PD genetics on diabetes
screening does not take into account the full complement
of clinical and genetic information contributing to nongly-
cemic variation in HbA1c, some of which may raise, and
not lower, HbA1c, thus reducing the risk of under-detec-
tion.41 For instance, structural variants (e.g., copy number
variation) were not included in our analyses. Nevertheless,
our findings highlight the potential for underdiagnosis in
carriers of these variants, which disproportionately affects
certain ethnic minorities, if HbA1c is used as the only diag-
nostic test for diabetes. Our sample sizes, and thus our
power, are limited compared to GWAS, particularly for His-
panic and Asian populations. For instance, we did not
detect an association signal for rs76723693 in HA because
only one individual in our HA population carried a copy of
the rare variant. Including larger samples of individuals of
non-European ancestries will improve the characterization
of rare variants with clinically meaningful effects on
HbA1c. We acknowledge that the genome-wide threshold
used in this paper may not represent the true number of in-
dependent genetic variants (SNVs as well as insertion-dele-
tion variants) tested using our sequence data.
In this study, we identified common and rare genetic var-
iants that cause nonglycemic differences in HbA1c with
important clinical and public health implications. Because
HbA1c is commonly used in diabetes screening and man-
agement worldwide, disregarding the effects of these rare
and common genetic variants that tend to occur in high
diabetes-risk minority groups could result in delayed diag-
nosis or under-detection of diabetes in carriers of these var-
iants. To avoid such disparities in care, an assessment of
these variants should be considered for incorporation into
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